SCHEMBL266723

SCHEMBL266723

CC(=O)O[C@H](C(=O)O)c1ccc(F)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.50
CYP3A4 P08684 1/20 0.50
CYP19A1 P11511 2/20 0.40
TSHR P16473 1/20 0.40
PPARG P37231 1/20 0.40
PPARA Q07869 1/20 0.40
HSD17B10 Q99714 1/20 0.39
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC10 Q969S8 1/20 0.39
HDAC11 Q96DB2 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HDAC9 Q9UKV0 1/20 0.39
HDAC5 Q9UQL6 1/20 0.39
POLB P06746 1/20 0.38
HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL266721 1.00 ALDH1A1 (0.50) ALDH1A1CYP3A4CYP19A1TSHRPPARG
SCHEMBL266722 1.00 ALDH1A1 (0.50) ALDH1A1CYP3A4CYP19A1TSHRPPARG
SCHEMBL14575920 0.84 ALDH1A1 (0.45) ALDH1A1CYP3A4CYP19A1TSHRHSD17B10
SCHEMBL5362478 0.84 ALDH1A1 (0.45) ALDH1A1CYP3A4CYP19A1TSHRHSD17B10
SCHEMBL8069856 0.83 ALDH1A1 (0.51) ALDH1A1CYP3A4TSHRHSD17B10POLB
SCHEMBL8068274 0.83 CYP3A4 (0.51) ALDH1A1CYP3A4TSHRHSD17B10LMNA
SCHEMBL28970488 0.83 ALDH1A1 (0.45) ALDH1A1CYP3A4CYP19A1TSHRHSD17B10
SCHEMBL27918530 0.82 HDAC3 (0.42) ALDH1A1CYP3A4CYP19A1HDAC3HDAC4
SCHEMBL1286155 0.82 ALDH1A1 (0.70) ALDH1A1CYP3A4TSHRPPARAHSD17B10
SCHEMBL628737 0.82 ALDH1A1 (0.70) ALDH1A1CYP3A4TSHRPPARAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8133909-B2 Heteroaromatic monoamides as orexinin receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
EP-2297102-A1 HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2011-03-23 EP disclosed
WO-2009153180-A1 HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-12-23 WO disclosed
US-20090312314-A1 HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312314-A1 HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPSR1 ALDH1A1 1706/4885CYP3A4 1262/4885CYP19A1 297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.